全國服務(wù)咨詢熱線：
18438616290
18438616290
簡(jiǎn)要描述：Cevimeline hydrochloride hemihydrate 153504-70-2Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
產(chǎn)品型號(hào)：abs47028023a廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2026-01-13訪 問 量：667產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 153504-70-2 |
|---|---|---|---|
| 分子式 | C20H38Cl2N2O3S2 | 純度 | ＞98% |
| 分子量 | 489.55 | 貨號(hào) | abs47028023 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a candidate therapeutic drug | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Cevimeline hydrochloride hemihydrate 153504-70-2
| 產(chǎn)品描述 | |
| 描述 | Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. |
| 純度 | ＞98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 鹽酸西維美林半水合物；SNI-2011；AF102B hydrochloride hemihydrate |
| 外觀 | white to tan powder |
| 可溶性/溶解性 | H2O : ≥ 50 mg/mL (204.27 mM) |
| 生物活性 | |
| In vitro(體外研究) | In digested parotid cells, Cevimeline (0.1-100 μM) increases the intracellular Ca2+ concentration. |
| In vivo(體內(nèi)研究) | Cevimeline (0.008-0.016 mg/kg; intraperitoneal injection; male Wistar rats) treatment shows slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response. Cevimeline inhibits angiotensin II-induced water intake and neuronal activity in the subfornical organ at 0.016 mg/kg. |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Neuroscience Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：
傳真：